Haemocell (UK) on road to recovery
This article was originally published in Clinica
Although Haemocell (UK) reported much improved revenues for the year ended August 31st, 1995, pretax losses increased to £2.52 million ($3.8 million) from £2.35 million in fiscal 1994. This is attributed to exceptional expenses of £404,000 resulting from actions to reduce costs. The increased turnover - from £212,000 in 1994 to £642,000 - reflects a recovery from the termination of Stryker's marketing deal for Haemocell's System 350 autologous blood transfusion system (see Clinica No 564/5, p 2). The UK company has established 37 distributors in 39 countries.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.